Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

14.23 +0.13 (+0.90%)
Streaming Delayed Price Updated: 3:21 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71,309
Open 14.34
Bid (Size) 14.20 (100)
Ask (Size) 14.23 (400)
Prev. Close 14.10
Today's Range 13.96 - 14.34
52wk Range 9.220 - 19.60
Shares Outstanding 24,296,259
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
From NeuroPace, Inc.
Via Business Wire

Performance

YTD
-6.2%
-6.2%
1 Month
-0.4%
-0.4%
3 Month
-6.2%
-6.2%
6 Month
+4.9%
+4.9%
1 Year
+45.2%
+45.2%

More News

Read More
News headline image
NeuroPace Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
From NeuroPace, Inc.
Via Business Wire
NeuroPace (NASDAQ:NPCE) Beats Q1 Estimates, Raises Full-Year Revenue Guidance ↗
Via Chartmill
NeuroPace Inc (NASDAQ:NPCE) Beats Q4 2025 Estimates and Reiterates 2026 Outlook ↗
Via Chartmill
News headline image
NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data ↗
Via MarketBeat
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace (NPCE) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
NeuroPace Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Present at the Leerink Global Healthcare Conference
From NeuroPace, Inc.
Via Business Wire
News headline image
Why NeuroPace Stock Was Inching Higher on Wednesday ↗
Via The Motley Fool
News headline image
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
From NeuroPace, Inc.
Via Business Wire

Frequently Asked Questions

Is Neuropace, Inc. - Common Stock publicly traded?
Yes, Neuropace, Inc. - Common Stock is publicly traded.
What exchange does Neuropace, Inc. - Common Stock trade on?
Neuropace, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neuropace, Inc. - Common Stock?
The ticker symbol for Neuropace, Inc. - Common Stock is NPCE on the Nasdaq Stock Market
What is the current price of Neuropace, Inc. - Common Stock?
The current price of Neuropace, Inc. - Common Stock is 14.23
When was Neuropace, Inc. - Common Stock last traded?
The last trade of Neuropace, Inc. - Common Stock was at 09/17/26 03:21 PM ET
What is the market capitalization of Neuropace, Inc. - Common Stock?
The market capitalization of Neuropace, Inc. - Common Stock is 345.65M
How many shares of Neuropace, Inc. - Common Stock are outstanding?
Neuropace, Inc. - Common Stock has 346M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS